Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients (PRARE-CHB)

Amira Mohamed Zidan

Status: Not yet enrolling

Conditions: Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection

Study type: Observational

Funder types: Other

Identifiers

NCT07274345

Soh-Med--25-11-5MS

Details and patient eligibility

About

This study aims to determine the prevalence of antiviral drug resistance among Egyptian patients with chronic hepatitis B virus (HBV) infection and to identify the associated demographic, clinical, and virological risk factors. Understanding patterns of resistance will help improve treatment selection and optimize long-term management strategies for HBV patients.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• This study will include all chronic HBV-infected patients, either cirrhotic or not, receiving TDF 300 mg, ETV 0.5 or 1mg, or lamivudine 100 mg, irrespective of HBeAg status. The HBV chronicity is defined by persistence of HbsAg positivity for more than 6 months.

Exclusion criteria

• Patients younger than 18 years old.

Trial design

2,000 participants in 1 patient group

This cohort includes adult Egyptian patients diagnosed with chronic hepatitis B virus (HBV) infectio